Products
Halofuginone is commercially available as an oral solution as a veterinary drug. It has been approved in many countries since 2003.
Structure and properties
Halofuginone (C16H17BrClN3O3, Mr = 414.7 g/mol) is a quinazoline derivative.
Effects
Halofuginone (ATCvet QP51AX08) has antiprotozoal properties against .
Indications
For the treatment of diarrhea caused by (cryptosporidiosis) in newborn calves.